1246815-28-0
1246815-28-0
Chemical Structure
Fenspiride-d5 hydrochloride
- CAS No.: 1246815-28-0
- Formula:C15H16D5ClN2O2
- Molecular Weight:301.82
IUPAC Name: 8-(phenethyl-d5)-1-oxa-3,8-diazaspiro[4.5]decan-2-one hydrochloride
InChIKey: FIKFLLIUPUVONI-GWVWGMRQSA-N
SMILES: O=C1OC2(CN1)CCN(CC2)CCC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H].Cl
Biological Activity: Fenspiride-d5 hydrochloride is the deuterium labeled Fenspiride hydrochloride (HY-A0027). Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fenspiride-d5 hydrochloride | Fenspiride-d5 hydrochloride is the deuterium labeled Fenspiride hydrochloride (HY-A0027). Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fenspiride hydrochloride (Standard) | ≥98% | Fenspiride (hydrochloride) (Standard) is the analytical standard of Fenspiride (hydrochloride). This product is intended for research and analytical applications. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fenspiride hydrochloride | 99.70% | Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Lebedenko AA, Mal'tsev SV. .[The efficacy of application of fenspiride (erespal) for the treatment of exacerbation of bronchial asthma in children.] Vestn Otorinolaringol. 2011;(4):66-67. [Content Brief]
